
    
      To assess the feasibility, tolerability and acceptability of 8 weeks of Desvenlafaxine (DESV)
      administration among opioid-dependent subjects in a methadone-maintenance program, we will
      collect detailed information on compliance to DESV treatment, side effects, methadone plasma
      levels, methadone dose changes and QTc measures.

      To explore the effects of DESV on depressive symptoms among opioid-dependent subjects on
      methadone-maintenance treatment. The severity and symptoms of depression will be evaluated by
      using the MADRS, the HRDS, and the CGI scale.

      To explore the effects of DESV on substance use, anxiety, craving, quality of life and
      suicidal risk.
    
  